Development of mitochondrial targeting plasmid DNA nanoparticles: Characterization and in vitro studies

作者：Salvado Ruben; Sousa Fani; Queiroz Joao; Costa Diana^*

来源：Colloids and Surfaces A: Physicochemical and Engineering Aspects , 2015, 480: 287-295.

DOI：10.1016/j.colsurfa.2014.12.013

• Plasmid DNA
• Non-viral vectors
• Nanoparticles
• Targeted delivery
• Mitochondrial gene therapy

Mutations in mitochondrial DNA are a frequent cause of metabolic and neuromuscular cytopathies and appear associated with Parkinson's and Alzheimer's diseases, diabetes, cancer and, with both premature aging and mortality worldwide. Although considered greater scourges of modern life, there is no clear consensus regarding an effective therapeutics. The development of gene therapy to treat mitochondrial DNA disorders offers a promising approach. Our group followed a co-precipitation method to formulate mitochondrial targeted rhodamine plasmid DNA based delivery systems, as a first step, for mitochondrial gene therapy implementation. To test the influence of plasmid size and composition on both the interaction with mitochondria and transfection efficiency, three different plasmids (pCAG-GFP, pcDNA3-myc-FLNaS2152A and pVAX1-LacZ) have been used. All systems are biocompatible and have suitable size and morphology for gene delivery purposes. Rhodamine associated fluorescence in isolated mitochondria show pCAG-GFP internalization into this organelle. Furthermore, GFP protein inexpression, mediated by rhodamine carriers, is consistent with the ability displayed by this nanosystem to target mitochondria; due to the different genetic code, fluorescent GFP protein cannot be expressed. Additionally, targeted delivery of pcDNA3-myc-FLNa S2152A and pVAX1-LacZ based vectors to mitochondria has been confirmed by fluorescence confocal microscopy. This work represents a significant step into the development of a mitochondrial therapeutic vector, greatly contributing for advances in the mitochondrial gene therapy field.

• 出版日期2015-9-5